AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 211 min read$NUVB

Hattersley Gary sold $709K of NUVB

Hattersley Gary (CHIEF SCIENTIFIC OFFICER) sold 100,000 shares of Nuvation Bio Inc. (NUVB) at $7.09 ($0.71M total) on 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hattersley Gary
Published Aug 21, 2026, 8:49 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NUVB
Bearish
medium confidence
Mentioned
$NUVB
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NUVBBearishLow
01

Why it matters

The CSO's complete exit could be interpreted as a negative signal, but the 10b5‑1 plan suggests pre‑planned execution.

02

Market read

Primary insider sale with modest size; limited trading impact but worth noting for risk‑aware investors.

03

What to watch

Potential upcoming clinical milestones that could offset negative perception.

Relevance 4/10Novelty 4/10Timing: post‑filing 2026‑08‑21

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$NUVBBearishMedium confidence
Context

Chief Scientific Officer sold 100,000 shares for $709,240 via a 10b5-1 plan, reducing his stake to zero.

Expected impact

Modest short‑term downside pressure

Evidence & confidence

The sale size is modest relative to market cap, but the CSO exiting completely could be viewed negatively by investors.

Market effects

Sector

Limited impact on biotech sector; similar insider sales are common.

Regional

No regional effect beyond the company's own stock.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The sale may be purely portfolio rebalancing under a pre‑arranged plan, not a confidence signal.

Key entities

  • company
    Nuvation Bio Inc.

    Biotech firm developing RNA‑based therapeutics.

  • person
    Hattersley Gary

    Chief Scientific Officer of Nuvation Bio.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NUVB insider trading history →

Related articles

AUG 22
$NUVBMed

JPMorgan sees 100% upside in overlooked cancer drug stock

JPMorgan initiated coverage of Nuvation Bio (NUVB) with an Overweight rating and a $13 price target, implying 100% upside. The bank cited strong sales of IBTROZI, a lung cancer drug launched in 2026, and potential from safusidenib, an experimental brain tumor drug. Nuvation reported Q2 2026 revenue of $31.7M, beating estimates, but still operating at a loss. The stock has fallen 18% YTD but gained 8% in the past five days.

yahoo.com3 min
AUG 21
$NUVBHighAI 8/10

Why is Nuvation Bio stock rallying today?

Nuvation Bio (NUVB) stock rose 2.8% to $7.02 after the FDA granted Fast Track Designation to safusidenib, its therapy for IDH1-mutant glioma, citing Phase 2 study data. Cantor Fitzgerald initiated coverage with an Overweight rating and $12 price target, projecting peak sales of $965M for IBTROZI and $1.9B for safusidenib. The broader market also showed gains.

investing.com2 min
AUG 21
$NUVBHigh

Nuvation Bio stock rises after Cantor starts at Overweight

Nuvation Bio (NUVB) shares rose 2.7% after Cantor Fitzgerald initiated coverage with an Overweight rating and $12 price target. Analyst Li Watsek highlighted two therapies, Ibtrozi and safusidenib, with peak sales estimates of $965M and $1.9B respectively, suggesting significant upside. Cantor also noted potential strategic interest in the company.

investing.com1 min
AUG 13
$NUVBMedAI 8/10

Nuvation Bio (NUVB) Q2 2026 Earnings Call Transcript

Nuvation Bio (NUVB) reported Q2 2026 revenue of $31.7M, including $23.2M IBTROZI product revenue and $8.5M collaboration and license revenue. IBTROZI net product revenue grew 25% QoQ to $23.2M, with 160 new patient starts. Net loss was $62.8M. Cash and marketable securities were $661M. The company raised $279.1M via convertible notes and expects a potential $30M Eisai EU milestone in 1H 2027.

fool.com10 min